|
|
Attenuated
veterinary virus vaccine for the treatment of cancer
Csatary
LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary
CM
United
Cancer Research Institute, Alexandria, VA
Attenuated
(nonpathogenic) avian viruses have been used as a form of nonspecific
immunological treatment for advanced human cancer.
For this study, we used Newcastle disease virus (NDV) vaccine MTH-68/N in an
open phase II/B, placebo-controlled (26 patients), multicenter clinical trial
for the treatment of 33 patients with advanced cancers.
NDV (4000 U/day) or placebo was administered by inhalation twice weekly.
During the 6-month trial, the size and presence of primary tumors and metastases
were objectively monitored at five institutions by radiologists unaware of the
type of treatment that was given.
Regression of tumor(s) and/or metastases were observed in eight cases treated
with virus (vs. none in the placebo group; p < 0.01).
Ten additional patients treated with NDV had no further progression of their
tumor sizes, whereas tumor stabilization was noted in only two control patients.
Objective, favorable responses (regressions plus stabilization) to virus therapy
thus occurred in a total of 18 patients (55%) compared to 2 patients in the
placebo group (8%; p < 0.01).
Two cases of complete remission were noted in the group treated with NDV.
Patients receiving virus therapy had a higher rate of survival at 1 to 2 years.
Of 33 patients receiving virus vaccine, 22 survived 1 year, compared to only 4
of 26 patients in the control group (p < 0.02). After 2 years, all seven
survivors in the study were in the virus therapy group.
There were no 2-year survivors in the control group (p < 0.0001).
(ABSTRACT TRUNCATED AT 250 WORDS)
PMID:
8275514 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8275514&dopt=Abstract
|
